lithium 2-amino-6-chloro-nicotinate | 906815-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: lithium 2-amino-6-chloro-nicotinate
• 英文别名: lithium 2-amino-5-chloronicotinate；lithium 2-amino-6-chloronicotinate；lithium;2-amino-6-chloropyridine-3-carboxylate
• CAS: 906815-93-8
• 化学式: C₆H₄ClN₂O₂*Li
• 分子量: 178.504
• InChiKey: YZYXONZYTASXKU-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.32
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  lithium 2-amino-6-chloro-nicotinate 在 盐酸 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 以46%的产率得到(2-amino-6-chloropyridin-3-yl)-[4-[(2S)-4-[3-chloro-5-[5-(ethylamino)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]-2-ethylpiperazin-1-yl]piperidin-1-yl]methanone
  参考文献：
  名称：

  WO2006/88840

  摘要：

  公开号：
• 作为产物：
  描述：

  2,5-二氯烟酸 在 lithium hydroxide 、 氯化亚砜 、 氨 、 水 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 289.5h， 生成 lithium 2-amino-6-chloro-nicotinate
  参考文献：
  名称：

  WO2007/109238

  摘要：

  公开号：

文献信息

• Substituted heterocyclic compounds with CXCR3 antagonist activity
  申请人：Kim Heon Seong

  公开号：US20070082913A1

  公开（公告）日：2007-04-12

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或其对映体、立体异构体、转构体、互变异构体、消旋体或前药，或该化合物的药用可接受的盐、溶剂合物或酯，或该前药的盐、溶剂合物或酯，其中所述化合物具有如下所示的一般结构：或其药用可接受的盐、溶剂合物或酯，其中各种基团在此处被定义。还公开了一种治疗趋化因子介导疾病的方法，例如，对炎症性疾病（非限定性示例包括牛皮癣）、自身免疫疾病（非限定性示例包括类风湿关节炎、多发性硬化症）、移植排斥（非限定性示例包括同种移植排斥、异种移植排斥）、传染病（例如，结核性麻风病）、固定药物性皮疹、皮肤迟发型超敏反应、I型糖尿病、病毒性脑膜炎和肿瘤的姑息治疗、治愈性治疗、预防性治疗，使用Formula 1化合物。
• Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
  申请人：Anilkumar N. Gopinadhan

  公开号：US20060217392A1

  公开（公告）日：2006-09-28

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prod rug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转轮异构体、互变异构体、外消旋体或前药，或该化合物的药学上可接受的盐、溶剂化合物或酯，或该前药的药学上可接受的盐、溶剂化合物或酯，该化合物具有如式1所示的一般结构，或其药学上可接受的盐、溶剂化合物或酯。还公开了一种使用式1化合物治疗趋化因子介导的疾病的方法，例如缓解疗法、治疗疗法、预防性治疗某些疾病和情况，如炎症性疾病（非限制性例子包括牛皮癣），自身免疫性疾病（非限制性例子包括类风湿性关节炎、多发性硬化症），移植排斥（非限制性例子包括同种异体排斥、异种排斥），感染性疾病（例如结核性麻风），固定药物疹，皮肤迟发型超敏反应，眼科炎症，I型糖尿病，病毒性脑膜炎和肿瘤。
• Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
  申请人：Zeng Qingbei

  公开号：US20060276448A1

  公开（公告）日：2006-12-07

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转动异构体、互变异构体、外消旋体或前药，或该化合物的药物可接受的盐或溶剂，或该前药的药物可接受的盐、溶剂或酯，该化合物具有如图式1所示的一般结构，以及其药物可接受的盐、溶剂或酯。本申请还公开了一种使用图式1的化合物治疗趋化因子介导的疾病的方法，例如，缓解疗法、治愈疗法、预防疗法，如炎症性疾病（非限制性示例包括牛皮癣），自身免疫性疾病（非限制性示例包括风湿性关节炎、多发性硬化症），移植排斥（非限制性示例包括同种异体移植排斥、异种移植排斥），感染性疾病（例如，结核性麻风），固定药物性皮疹，皮肤延迟型超敏反应，眼部炎症，1型糖尿病，病毒性脑膜炎和肿瘤。
• Piperazine-piperidines with CXCR3 antagonist activity
  申请人：Yu Wensheng

  公开号：US20060276457A1

  公开（公告）日：2006-12-07

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请公开了一种化合物，或该化合物的对映体、立体异构体、转轮异构体、互变异构体、外消旋体或前药，或该化合物的药学上可接受的盐、溶剂化物或酯，或该前药的药学上可接受的盐、溶剂化物或酯，该化合物具有如公式1所示的通用结构，其中各种基团在此定义。还公开了一种使用公式1的化合物治疗趋化因子介导的疾病的方法，例如，治疗炎症性疾病（非限制性示例包括牛皮癣）、自身免疫性疾病（非限制性示例包括类风湿性关节炎、多发性硬化症）、移植排斥（非限制性示例包括同种异体排斥、异种排斥）、传染病（例如结核性麻风）、固定药物性皮疹、皮肤迟发型超敏反应、眼部炎症、1型糖尿病、病毒性脑膜炎和肿瘤的姑息治疗、治愈性治疗、预防性治疗和条件。
• Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
  申请人：Wong K. C. Michael

  公开号：US20060276480A1

  公开（公告）日：2006-12-07

  The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

  本申请披露了一种化合物，或其对映体、立体异构体、转轮异构体、互变异构体、外消旋体或前药，或该化合物的药学上可接受的盐、溶剂化合物或酯，或该前药的药学上可接受的盐、溶剂化合物或酯，该化合物具有如公式1所示的通用结构，以及其药学上可接受的盐、溶剂化合物和酯。还披露了一种治疗趋化因子介导疾病的方法，例如对于炎症性疾病（非限定性示例包括银屑病）、自身免疫性疾病（非限定性示例包括类风湿性关节炎、多发性硬化症）、移植排斥（非限定性示例包括同种移植排斥、异种移植排斥）、感染性疾病（例如结核性麻风）、固定药物性皮疹、皮肤延迟型超敏反应、眼部炎症、1型糖尿病、病毒性脑膜炎和肿瘤使用公式1的化合物。